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Available online 22 June 2018Background: Ectopic pregnancies are a leading cause of maternal mortality. Most are treated surgically. We eval-
uated the efﬁcacy and safety of combining oral geﬁtinib (epidermal growth factor receptor inhibitor) withmeth-
otrexate to treat larger ectopic pregnancies.
Methods: We performed a phase II, single arm, open label study across four hospitals in Edinburgh and Mel-
bourne. We recruited women with a stable tubal ectopic pregnancy and a pre-treatment serum hCG between
1000 and 10,000 IU/L. We administered intramuscular methotrexate (50 mg/m2) once, and oral geﬁtinib
(250mg) for seven days. The primary outcomewas the percentage successfully treatedwithout needing surgery.
To show the treatment is at least 70% effective, 28 participantswere required, and 24 ormore successfully treated
without surgery. Secondary outcomes were safety, tolerability, and time to resolution. This study is registered
(ACTRN12611001056987).
Findings: 30 participants with stable tubal ectopic pregnancies were recruited but two withdrew, leaving 28 par-
ticipants. The median (± range) pre-treatment serum hCG was 2039 (1031–8575) IU/L and nine had pre-
treatment hCGs levels N3000 IU/L. The treatment successfully resolved 86% (24/28) cases with a median (±
range) time to resolution of 32 (18–67) days. The treatment caused transient rash and diarrhoea, but no serious
adverse events.
Interpretation: Combination geﬁtinib and methotrexate is at least 70% effective in resolving ectopic pregnancies
with a pre-treatment serum hCG 1000–10,000 IU/L. Thismay be a newway to treatmost stable ectopic pregnan-
cies, but needs to be validated via a randomised clinical trial.
Crown Copyright © 2018 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Phase II1. Introduction
Ectopic pregnancy complicates 1–2% of pregnancies [1] and is the
most common life-threatening condition in early pregnancy. In the
United Kingdom, there are 12,000 cases of ectopic pregnancy everyand Gynaecology, University of
Studley Rd., Heidelberg 3084,
r B.V. This is an open access article uyear and they contribute to 3–8% of all maternal pregnancy related
deaths [2]. 98% are tubal ectopic pregnancies where the pregnancy im-
plants in the Fallopian tube.
Ectopic pregnancies can be treated surgically (mainly by operative
laparoscopic excision), or medically (intramuscular injection of the fo-
late antagonist, methotrexate, followed by serial monitoring of serum
hCG concentrations) [3]. However, the efﬁcacy of methotrexate treat-
ment is lower with higher pre-treatment serum hCG concentrations
[3]. Hence, many cases are still treated surgically [3] and there is a
need for a more effectivemedical therapy to reduce operative interven-
tion (and its inherent risks) in women diagnosed with ectopic
pregnancy.nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Research in context
Evidence before this study
We searched PubMed for articles beforeMay 31stwithout restric-
tion on the start date.We included the search terms “ectopic preg-
nancy”, AND “treatments” AND “gefitinib”. There is already an
extensive literature evaluating the use ofmethotrexate to treat ec-
topic pregnancies, and reviewing each of these trials was beyond
the remit of our current study. Hence for methotrexate treatment
we examined meta-analyses’, reviews and international clinical
guidelines on the medical management of ectopic pregnancies.
We also searched for general reviews on the topic of ectopic preg-
nancy treatment (search terms “ectopic pregnancy”AND “review).
Most ectopic pregnancies are treated surgically. An injection of
methotrexate is now widely used clinically to treat ectopic preg-
nancy. However, the efficacy of methotrexate declines with in-
creasing pre-treatment serum human chorionic gonadotrophin
(hCG) levels, and declines in the presence when other clinical pa-
rameters are present that suggests the presence of a large ectopic
pregnancy (demonstrable fetal cardiac activity or a large size seen
on ultrasound). One systematic meta-analysis published 10 years
ago concluded that methotrexate treatment is only more cost
economical than surgery if the pre-treatment serum hCG is
b1500 IU/L.
A preclinical laboratory study identified the possibility that com-
bining gefitinib (an orally available epidermal growth factor recep-
tor inhibitor) withmethotrexatemay be additive in treating ectopic
pregnancies, compared to either agent alone. There have also
been two early phase clinical studies published. The first was a
trial of 12 participants where the inclusion criteria was an ectopic
pregnancy with a pre-treatment hCG b3000 IU/L. It showed the
treatment appeared safe, and a comparison with a historic cohort
of women treated with methotrexate alone suggested adding ge-
fitinibmay induce faster declines in serumhCG levels and resolves
the ectopic pregnancy faster. The second human study was a
case series that showed combination gefitinib and methotrexate
resolved eight cases of extra-tubal ectopic pregnancies.
Added Value of This Study
This is the first study evaluating the potential of combination gefi-
tinib and methotrexate in treating tubal ectopic pregnancies pre-
senting with pre-treatment hCG levels between 1000-10,000
IU/L. This single arm clinical trial of 28 participants found combin-
ing seven tablets of gefitinib with methotrexate resolved 86% of
ectopic pregnancies in a cohort that included larger ectopic preg-
nancies.
Implications of all the Available Evidence
Collectively, three single arm human trials suggest combination
gefitinib and methotrexate may be a newmedical treatment to re-
solve most ectopic pregnancies. However, the concept now
needs to be tested in large randomized clinical trial before it can
be used clinically.
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(where methotrexate is in widespread clinical use), it is clear that out-
comes are improvedwith combination treatments which target different
aetiological pathways, compared to single agent treatment. We propose
that the addition of oral geﬁtinib (an epidermal growth factor receptor
[EGFR] antagonist) to the current medical management regimen ofintramuscular methotrexate could provide an exciting clinical solution
to the suboptimal medical therapy currently available for the manage-
ment of ectopic pregnancy. Geﬁtinib is a molecularly targeted drug that
blocks EGFR signalling, and is licensed to treat non-small-cell lung cancer.
In preclinical studies,wehave shown that ectopic pregnancy implan-
tation sites (trophoblast cells) express high levels of EGFR and that geﬁ-
tinib augments methotrexate-induced regression of pregnancy-like
tissue [4]. Importantly, the two agents work additively in trophoblast
cells to potently inhibit cell growth, block EGFR signalling pathways,
and enhance apoptosis.
We previously reported a Phase I (Geﬁtinib and Methotrexate Trial 1,
or GEM1) single-arm open-label dose-escalation study administering a
combination of intramuscular methotrexate (50 mg/m2, standard care)
and 250 mg oral geﬁtinib (one dose (n = 3), three daily doses (n = 3),
seven daily doses (n = 6)) to 12 women with ectopic pregnancy
(serum hCG b3000 IU/L) [5]. The combination of methotrexate and geﬁ-
tinib did not cause any signiﬁcant toxicities (assessed clinically and by se-
rial biochemical assessment) or serious side effects. We have also
reported a case series where we successfully treated eight extra-tubal ec-
topic pregnancieswith geﬁtinib andmethotrexate [6].While preliminary,
the collective data from the preclinicalwork and the two small early trials
suggest combination methotrexate and geﬁtinib merit further consider-
ation as an effective medical treatment for ectopic pregnancy.
We therefore undertook a phase II clinical trial. Importantly, we
wanted to examinewhether the treatment is efﬁcacious in treating larger
tubal ectopic pregnancies where current medical management is more
likely to fail. We set out to recruit tubal ectopic pregnancies with pre-
treatment serum hCG concentrations between 1000 and 10,000 IU/L.
2. Materials and Methods
We conducted a phase II single-arm multi-centre open label trial to
examine the efﬁcacy and safety of a single dose of intramuscular meth-
otrexate and daily oral geﬁtinib for seven days to treat tubal ectopic
pregnancies (Trial registration number: ACTRN12611001056987). We
named this the GEM (Geﬁtinib andMethotrexate) II study and the pro-
tocol has previously been published [7]. This was an investigator led
project and the funders had no role in the conduct of the study.
In women with stable tubal ectopic pregnancy with hCG concentra-
tions between 1000 and 10,000 IU/L we expected the success of metho-
trexate treatment (deﬁned as a decline in serum hCG b 15 IU/L without
the need for surgery) to be 70% or less. Using A'Hern's formula for Phase
II one-stage designs [8], with 80% power and a 5% level of signiﬁcance,
28 patients were required to enable us to assess whether the proportion
of patients with a successful outcome to treatment was N70%. The reason
we selected this ﬁgure is thatmethotrexate in the clinic appears to have a
success rate of around 70% [9, 10]. Our power calculation found if 24 or
more patients have a successful outcome, we can reject the hypothesis
that the true efﬁcacy of combination geﬁtinib and methotrexate is ≤70%.
We recruited women presenting with tubal ectopic pregnancies
with a pre-treatment serum hCG concentration between 1000 and
10,000 IU/L who were considered clinically stable at four hospitals:
Royal Inﬁrmary of Edinburgh (Edinburgh, United Kingdom), Mercy
Hospital for Women (Victoria, Australia) and two hospitals within the
Monash Health Network (Monash Medical Centre and Dandenong Dis-
trict Hospital, both in Victoria, Australia). Ethical approval was obtained
from the Scotland A Research Ethics Committee (LREC 12/SS/0005)
(UK), the Southern Health Human Research Ethics Committee B (SH
HREC 11180B) and theMercy Health Human Research Ethics Committee
(R12/25). We obtained written, informed consent for all participants.
Our inclusion criteria were: women aged between 18 and 45 years;
pre-treatment serum hCG of 1000–10,000 IU/L (rising or static); ultra-
sounddiagnosis of deﬁnite tubal ectopic pregnancy (extrauterine gesta-
tional sacwith yolk sac and/or embryo, with orwithout cardiac activity)
or probable (inhomogeneous adnexal mass or extra-uterine sac-like
structure) performed by a clinical team of trained, qualiﬁed and
Table 1
Baseline characteristics (n = 28).
Characteristic
Age – (median and IQR) 30.5 (25.5–33.8)
Previous live births – n (%) 17 (61%)
Body mass index – (median and IQR) 27.0 (23.0–30.3)
Previous ectopic pregnancy - n (%) 6 (31%)
Self reported past history of pelvic infection 4 (14%)
Presence of a sexually transmitted infection - n (%)a 1 (4%)
Conception by assisted reproductive technology – n (%) 4 (14%)
Smoker
Never 15 (54%)
Past smoker 6 (21%)
Current smoker 7 (25%)
Body mass index was not recorded in 2 cases. IQR – Interquartile range.
a 23 out of the 28participantswere screened at recruitment for the presence of sexually
transmitted infections.
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bleeding; no pallor; no guarding/rigidity on abdominal examination;
stable blood pressure and heart rate; haemoglobin on full blood exam-
ination at day 1 between 100 and 165 g/L.
Our exclusion criteria were: women with a pregnancy of unknown
location; evidence of a signiﬁcant intra-abdominal bleed on ultrasound
deﬁned by freeﬂuid above the uterine fundus or surrounding the ovary;
women with a history of any signiﬁcant pulmonary disease; abnormal
liver/renal/haematological indices; signiﬁcant pre-existing dermatolog-
ical conditions; signiﬁcant pre-existing gastrointestinal medical ill-
nesses; and Japanese ethnicity (as those of Japanese descent who are
administered geﬁtinib have been reported to be at higher risk of devel-
oping interstitial lung disease) [11].
Our intervention was a single dose intramuscular methotrexate
(50 mg/m2) injection with seven daily doses oral geﬁtinib (250 mg).
We started the administration of geﬁtinib on the same day that the ﬁrst
methotrexate injection was given. To monitor treatment response, we
followed protocols to track serial serum hCG concentrations widely
used for medical management with methotrexate, and ﬁrst proposed
by Stovall et al. [12]. Serum hCG levels were measured on days 4, 7 and
11, then weekly until hCG levels declined to non-pregnant levels
(b15 IU/L). All womenwere reviewed regularly and subsequentmanage-
ment, anddecision for surgery,was based onnormal clinical care. Surgery
was considered if therewas a persistent lack of response to the treatment
(evidence of a lack of a fall in serum hCG concentrations) or there was
clinical evidence raising suspicions of active bleeding or tubal rupture.
To monitor safety and tolerability, women were assessed clinically
(history) and biochemically (haematological, renal and liver function
tests) on days 4 and 7 (or if elevated, they were offered repeat testing
until any abnormal values returned to normal physiological levels).
Our primary outcome was the resolution of the tubal ectopic preg-
nancy without the need for surgery. Resolution was deﬁned by serum
hCG concentrations (the current clinical marker tomonitor treatment re-
sponse) falling to non-pregnant levels (hCG b15 IU/L, which corresponds
to anegative urinary pregnancy test using themost sensitive assays). Fail-
ure was therefore deﬁned as women who required salvage surgery.
Our second outcome was to document safety, tolerability and ad-
verse events, as determined by clinical and biochemical assessment. Pa-
tients were regularly reviewed clinically and we conﬁrmed normal
renal, liver and haematological function tests on day 1 and assessed
treatment effects on days 4 and 7. Furthermore, participants were
asked to collect information about adverse events in treatment diaries.Fig. 1. Flow of participants recruited to the study.They were instructed to contact the clinical research team at any time
after consenting to join the trial if they have an event that requires
hospitalisation or an event that results in persistent or signiﬁcant dis-
ability or incapacity. The protocols and evaluation in place for serious
adverse event reporting are described in detail in the published study
protocol [9]. After treatment, participants were contacted at least 3
and 6 months post treatment to document return of menstrual cycles
and any subsequent pregnancies.
We also compared the numbers who were successfully treated
without need for surgery to women not enrolled in the trial, but pre-
sented to our clinical services during the period the trial was recruiting
participants and treated with methotrexate alone. These were women
diagnosed with tubal ectopic pregnancies presenting at our hospitals
with similar pre-treatment serum hCG levels during the time period
while we were recruiting for the trial, but either declined to participate
in our trial (or were not approached) andwere treatedwithmethotrex-
ate instead.
Given this was a single arm efﬁcacy trial, the data were expressed
using descriptive statistics. Comparisons of serum hCG levels were
done using the Mann-Whitney U test. Analysis and reporting followed
CONSORT guidelines. This was an investigator initiated trial, with no
funding from industry. ST, MMS and AWH had full access to all the
data in the study and had ﬁnal responsibility for the decision to submit
the data for publication.3. Results
We recruited 30womendiagnosedwith stable tubal ectopic pregnan-
cies with a pre-treatment serum hCG 1000–10,000 IU/L presenting be-
tween January 2012 and April 2014. Fig. 1 shows the ﬂow of participants.
Two participants withdrew soon after commencing treatment be-
cause they decided that they wanted surgical management (despiteTable 2
– Baseline characteristics of a contemporaneous cohort (n = 32).
Characteristic
Age – (median and IQR)
Previous live births – n (%) 14 (44%)
Body mass index – (median and IQR)a 25 (22–28)
Previous ectopic pregnancy - n (%) 3 (9%)
Self reported past history of pelvic infection, or a positive
Chlamydia test – n (%)b
6 (18%)
Conception by assisted reproductive technologies – n (%) 2 (6%)
Smoker – n (%)
Never 24 (75%)
Past smoker 4 (12.5%)
Current smoker 4 (12.5%)
a Body mass index was available for 26 women.
b Womenwho presented to theMelbourne Hospitals (but not Edinburgh)were offered
routine chlamydia testing during their treatment for their ectopic pregnancy, where 3
tested positive.
Fig. 2. Serum hCG concentrations among the 24 participants who were successfully
treated in the trial. Median and interquartile range shown. A) Aggregate serum hCG
levels. Median and interquartile range shown. B) Serum hCG of individual participants.
Black solid line – participants who had an initial rise in serum hCG before a decline.
Green dotted line – participants who had a slow but steady decline in serum hCG levels.
Blue dotted line – participants who had an acute fall in serum hCG levels.
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ture i.e. not due to evidence of treatment failure). As we did not plan an
intention to treat analysis, they were excluded from the analysis and we
continued to recruit participants until we reached our target of 28 cases.
The clinical baseline details of the 28 participants who met inclu-
sion criteria and participated in the study are shown in Table 1. The
median (range) pre- treatment serum hCG concentrations were
2039 (1031–8675) IU/L. Nine cases (32%) had a pre-treatment
serum hCG concentration above 3000 IU/L.
The ectopic pregnancies were successfully resolved with combina-
tion therapy in 24 participants (86%), the remaining four were offered
surgery. There was a signiﬁcant difference in pre-treatment hCG con-
centrations between the four requiring surgery (median 3500 (range
2876–7551) IU/L and the 24 successfully treated (median serum hCG
concentrations 1922 (range 1030–8575) IU/L; p = 0.012, Mann-
Whitney-U test)). There was only one case recruited where there was
fetal cardiac activity. The pre-treatment hCG concentration was
7551 IU/L and it was among the four cases that required surgery.
Among the 28 participants, there were 19 cases with a serum hCG
1000–3000 IU/L and of these, 18 were successfully treated (94.7% suc-
cess rate). Thus, most of the cases where salvage surgery was required
were those where the pre-treatment serum hCGwere above 3000 IU/L.
The treatment appeared safe and there were no reported serious ad-
verse events attributable to the medication and no biochemical
abnormalities seen on serial haematological and renal function testing.
A transient rash occurred in 16 (57%) of participants and 13 had diar-
rhoea, known side effects of geﬁtinib. Six participants had mild transient
elevations of serum liver enzyme levels (either elevatedAspartate amino-
transferase or Alanine aminotransferase levels, a possible side effect of
methotrexate) that then normalised with completion of the treatment.
Other non-serious side effects reported that may, or may not be attribut-
able to the trial medication were: 15 with nausea (2 reported vomiting),
10 reported lethargy, 8 had dizziness and 7 had pruritus.
Thus, none of our three single arm trials (the current report and our
prior early phase trials [5,6] identiﬁed a serious adverse event that was
likely to be attributed to the medication. A transient skin rash has been
noted to occur commonly (57% in this trial and 67% in our previous
phase I trial [5]) as well as diarrhoea and these are likely to be common
sides effects of this treatment.
We also obtained data froma contemporaneous cohort of 32women
diagnosed with a tubal ectopic pregnancy (with a pre-treatment serum
hCG concentration between 1000 and 10,000 IU/L) presenting to our in-
stitutions within the time period of the trial. These were women not re-
cruited to the trial, (either not approached or declined participation, see
Fig. 1) but instead, were treated medically with methotrexate.
Table 2 shows their baseline characteristics. The median (range)
pre-treatment serum hCG concentrations was 2083 (1058–4985) IU/L
and were no different to pre-treatment hCG concentrations of trial par-
ticipants (p= 0.71). Seven cases (22%) had a pre-treatment serum hCG
concentrations N3000 IU/L. Thus, baseline hCG levels appeared compa-
rable to the 28 trial participants.
In this contemporaneous cohort, medical management with either
one or two doses of methotrexate resolved the ectopic pregnancy with-
out the need for surgery in 66% of cases (n=21), lower than 86% rate of
success seen among the trial cohort although the comparison was not
statistically signiﬁcant (p = 0.08).
Up until February 2015 (the ﬁnal date we had permission from
ethics to contact women before we closed this study) there had been
seven subsequent spontaneous pregnancies in our trial cohort. Five
had been successful intrauterine pregnancies, one had a miscarriage
and another was diagnosed with another tubal ectopic pregnancy that
was treated surgically.
The median (±range) time to resolution for the 24 participants suc-
cessfully treated with combination methotrexate and geﬁtinib was 32
(18–67) days. Serum hCG levels among these 24 participants are illus-
trated in Fig. 2A. Eight participants had a transient increase in theirserum hCG concentrations before they declined (Fig. 2B – black solid
line) and seven experienced a steep decline in serum hCG concentra-
tions from the commencement of treatment (Fig. 2B – dotted blue
line). Serum hCG concentrations declined between days 4 and 7 after
the start of treatment among 22 out of the 24 (92%) participants who
were successfully treated.
4. Discussion
Intramuscular methotrexate with seven daily tablets of geﬁtinib
successfully resolved 86% of larger tubal ectopic pregnancies (hCG
1000–10,000 IU/L) without the need for ‘rescue’ surgery. Our pre-
speciﬁed power calculation suggests this treatment is at least 70% effec-
tive. The treatment commonly causes skin rash and diarrhoea but there
appeared to be no serious adverse events attributable to the studymed-
ication. Furthermore, seven participants subsequently had spontaneous
pregnancies.
The treatment trended towards beingmore effective when the rates
of treatment success were compared to a group of 32womenwhowere
administered methotrexate where 66% had treatment success. Of note,
the numbers we obtained who were administered methotrexate alone
were small. Despite this, there appeared to be a strong trend and it
raises the possibility that the combination treatment may be more
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alone but we were underpowered to detect this. Whether or not this
is in fact truly the case requires a randomised clinical trial but this
data supports the case to undertake one.
A strength of our study is that it was designed to examine the efﬁcacy
of geﬁtinib and methotrexate to treat larger ectopic pregnancies. Guide-
lines published by The Royal College of Obstetricians and Gynaecologists
[13] that were current at time we recruited women to our study recom-
mended women with an ectopic pregnancy and a pre-treatment serum
hCG b 3000 IU/L could be offered medical management but for those
above this threshold, surgery should be considered. Thus, a number of
our trial participants would have proceeded to surgery if they were of-
fered regular clinical care following our existing hospital protocols. We
note that since we completed this study, new guidelines on the manage-
ment of ectopic pregnancy published by RCOG in 2016 now suggests the
use of methotrexate may be suitable for ectopic pregnancies with a pre-
treatment hCG up to 5000 IU/L [14].
Furthermore, we also excluded smaller ectopic pregnancies with a
pre-treatment serumhCG b 1000 IU/L. Inclusion of such cases would im-
prove rates of success but dilute our ability to examine whether this
treatment is indeed effective in resolving larger ectopic pregnancies.
A limitation to our study is that it was a single arm design. We were
keen to test this intervention on larger ectopic pregnancies, including
those that would have been treated surgically. Therefore, there was no
obvious comparison group as it would have been unethical to mandate
medical treatment using methotrexate alone for those with larger ec-
topic pregnancies where it is known rates of success are perhaps unac-
ceptably low.
We previously published a phase I trial where we treated 12 partic-
ipants [5] with geﬁtinib and methotrexate. In contrast to the present
study, the prior report recruited women with a pre-treatment serum
hCG b 3000 IU/L (where six had a pre-treatment serum hCG
b 1000 IU/L and the remaining had a serum hCG between 1000 and
3000 IU/L). 85% (10/12)were successfully treatedwith the combination
treatment. In this present study there was a 86% success rate among the
entire cohort.
We also published a case series where we treated eight cases of
extra-tubal ectopic pregnancies [6]. Five were in the cornua and two
were embedded in an old caesarean section scar. Five had a pre-
treatment serum hCG N 5000 IU/L. All eight were successfully treated.
Other than these there are no other reports examining the use of geﬁ-
tinib to treat ectopic pregnancies.
As stated in our published protocol, we did not envisage thiswould be
the ﬁnal trial to determine whether combination geﬁtinib and metho-
trexate should be used clinically to treat ectopic pregnancies [7]. How-
ever, this phase II study has achieved the stated primary outcome
suggesting the efﬁcacy of this treatment to treat these larger tubal ectopic
pregnancies is greater that 70%. In light of the data obtained in this phase
II trial, we believe it supports progressing to a phase III randomised trial.
A systematic review andmeta-analysis analysing data from two clin-
ical trials [15] concluded that the cost-effectiveness of medical treat-
ment with methotrexate drops signiﬁcantly with higher (N1500 IU/L)
pre-treatment serum hCG and that laparoscopic excision remains the
most effective treatment for ectopic pregnancy [16]. Reasons for the in-
creased costs arising from medical management is the expense of out-
patient visits and that some participants will still require surgery after
a period of observation. If geﬁtinib and methotrexate where shown to
be more effective in a phase III clinical trial than methotrexate alone
and resolves them quicker (resulting in less outpatient visits), it may
also be worthwhile comparing the costs of the two treatments.
We have now commenced a phase III trial where we plan to
randomise 328 women diagnosed with an ectopic pregnancy with an
pre-treatment serum hCG b5000 IU/L to either methotrexate alone, or
methotrexate and seven daily oral tablets of geﬁtinib (GEM III trial; EU
Clinical Trials register: 2015-005013-76). We selected a pre-treatment
serum hCG cut-off of 5000 IU/L, as this is a threshold advocated by theNational Institute for Health and Care Excellence (NICE) [17], the
American College of Obstetricians and Gynecologists [18] and also the
Royal College of Obstetrician and Gynecologists [14] and makes it ethi-
cal to perform a placebo controlled trial comparing the combination
with methotrexate treatment alone. Our primary outcome for this
new trial is the need for surgical intervention in the resolution of the
tubal ectopic pregnancy. Should our phase III randomised trial yield a
positive result, this may represent sufﬁcient evidence to show adding
geﬁtinib to the current methotrexate protocol improves the efﬁcacy of
medical management, and this could become standard of care.
In conclusion, combination geﬁtinib andmethotrexatewas 86% (and
at least 70% effective) in resolving ectopic pregnancies with a pre-
treatment serum hCG 1000–10,000 IU/L. Transient diarrhoea and rash
are common side effects. This may be a new medical treatment to
treat most stable ectopic pregnancies, but a randomised clinical trial
needs to be completed before this can be used in the clinic.
Funding Sources
This work was supported by an NHMRC Grant (#1008276) to ST, TJ
and EW, and anMRC Centenary Award (G0802808) to AH. The funders
had no role study design, collection, analysis, and interpretation of data;
in the writing of the report or in the decision to submit the paper.
Declaration of Interests
TJ, and ST are joint holders of patents that relate to the use of EGFR
inhibition in treating ectopic pregnancies. There are no other conﬂicts
of interest to disclose.
Author Contributions
MMS set up the trial, recruited participants in Melbourne, analysed
the data and drafted the paper. S.T. helped design the trial, obtained
funding, supervised recruitment in Melbourne, provided oversight for
the trial, helped analyse the data and drafted the initial versions of the
paper. A.D. helped design the trial and co-ordinated the trial in Edin-
burgh, supervising recruitment. J.M. helped design the trial, providing
statistical input in both the design and in theﬁnal analysis. TGJ provided
input in the analysis and drafting of the paper. PN, MR, and NK helped
with recruitment in Melbourne. EW obtained funding for the trial. SB
provided input in the design and drafting of the paper. WCD helped
with the design of the trial, provided supervision of the trial in Edin-
burgh. AWH designed the protocol, helped set up the trial in Edinburgh,
supervised recruitment in Edinburgh and provided oversight for the
trial with ST, helped analyse the data and drafted the initial versions
of the paper. All authors contributed to the drafting of the paper.
Acknowledgements
We thank staff at The Early Pregnancy Unit at The Royal Inﬁrmary of
Edinburgh and all participants of this study.
References
[1] Anon. Ectopic pregnancy: United States, 1990–1992. , 44MMWR Morbidity Mortal-
ity Weekly Report; 1995; 46–8.
[2] The Conﬁdential Enquiry into Maternal and Child Health (CEMACH). Saving
mother's lives: Reviewing maternal deaths to make motherhood safer 2003–2005.
The seventh report on conﬁdential enquiries into maternal deaths in the United
Kingdom London; 2007.
[3] Jurkovic D, Wilkinson H. Diagnosis and management of ectopic pregnancy. BMJ
2011;342:d3397.
[4] Nilsson UW, Johns TG,Wilmann T, et al. Effects of geﬁtinib, an epidermal growth fac-
tor receptor inhibitor, on human placental cell growth. Obstet Gynecol 2013;122(4):
737–44.
[5] Skubisz MM, Horne AW, Johns TG, et al. Combination geﬁtinib and methotrexate
compared with methotrexate alone to treat ectopic pregnancy. Obstet Gynecol
2013;122(4):745–51.
281M.M. Skubisz et al. / EBioMedicine 33 (2018) 276–281[6] Horne AW, Skubisz MM, Tong S, et al. Combination geﬁtinib andmethotrexate treat-
ment for non-tubal ectopic pregnancies: A case series. Hum Reprod 2014;29(7):
1375–9.
[7] Horne AW, Skubisz MM, Doust A, et al. Phase II single arm open label multicentre
clinical trial to evaluate the efﬁcacy and side effects of a combination of geﬁtinib
and methotrexate to treat tubal ectopic pregnancies (GEM II): Study protocol. BMJ
Open 2013;3(7).
[8] A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001;
20(6):859–66.
[9] Skubisz M, Dutton P, Duncan WC, Horne AW, Tong S. Using a decline in serum hCG
between days 0–4 to predict ectopic pregnancy treatment success after single-dose
methotrexate: A retrospective cohort study. BMC Pregnancy Childbirth 2013;13:30.
[10] Avcioglu SN, Altinkaya SO, Kucuk M, Demircan Sezer S, Yuksel H. Predictors of suc-
cess of different treatment modalities for management of ectopic pregnancy. Obstet
Gynecol Int 2014;2014:423708.
[11] Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-
cell lung cancer with erlotinib or geﬁtinib. N Engl J Med 2011;364(10):947–55.
[12] Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatment of ectopic
pregnancy. Obstet Gynecol 1991;77(5):754–7.[13] Royal College of Obstetricians and Gynaecologists. The management of tubal preg-
nancy. GreenTop guideline No 21 (Updated 2010); 2004.
[14] Royal College of Obstetricians and Gynaecologists. Diagnosis andmanagement of ec-
topic pregnancy. Green-top guideline No.21; 2016www.rcog.org.uk/en/guidelines-
research-services/guidelines/gtg21/.
[15] Sowter MC, Farquhar CM, Gudex G. An economic evaluation of single dose systemic
methotrexate and laparoscopic surgery for the treatment of unruptured ectopic
pregnancy. BJOG 2001;108(2):204–12.
[16] Mol F, Mol BW, Ankum WM, van der Veen F, Hajenius PJ. Current evidence on sur-
gery, systemic methotrexate and expectant management in the treatment of tubal
ectopic pregnancy: A systematic review and meta-analysis. Hum Reprod Update
2008;14(4):309–19.
[17] Ectopic pregnancy andmiscarriage. Diagnosis and initial management in early preg-
nancy of ectopic pregnancy and miscarriage. NICE clinical guidelines; 2012. p. 154
guidance nice.org.uk/cg154.
[18] American College of O, Gynecologists. Medical management of ectopic pregnancy.
Obstet Gynecol 2008;111(6):1479–85 (ACOG Practice Bulletin No. 94).
